BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18155247)

  • 1. Effects of medications on plasma amyloid beta (Abeta) 42: longitudinal data from the VITA cohort.
    Blasko I; Jungwirth S; Jellinger K; Kemmler G; Krampla W; Weissgram S; Wichart I; Tragl KH; Hinterhuber H; Fischer P
    J Psychiatr Res; 2008 Sep; 42(11):946-55. PubMed ID: 18155247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy.
    Blasko I; Kemmler G; Krampla W; Jungwirth S; Wichart I; Jellinger K; Tragl KH; Fischer P
    Neurobiol Aging; 2005; 26(8):1135-43. PubMed ID: 15917096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
    Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels.
    Fukumoto H; Tennis M; Locascio JJ; Hyman BT; Growdon JH; Irizarry MC
    Arch Neurol; 2003 Jul; 60(7):958-64. PubMed ID: 12873852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
    Gurol ME; Irizarry MC; Smith EE; Raju S; Diaz-Arrastia R; Bottiglieri T; Rosand J; Growdon JH; Greenberg SM
    Neurology; 2006 Jan; 66(1):23-9. PubMed ID: 16401840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Buchhave P; Andreasson U; Londos E; Minthon L; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(5):316-20. PubMed ID: 17374949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level.
    Pesaresi M; Batelli S; Prato F; Polito L; Lovati C; Scarpini E; Quadri P; Mariani C; Albani D; Forloni G
    Neurobiol Dis; 2007 Mar; 25(3):609-13. PubMed ID: 17174555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly.
    Qiu WQ; Sun X; Selkoe DJ; Mwamburi DM; Huang T; Bhadela R; Bergethon P; Scott TM; Summergrad P; Wang L; Rosenberg I; Folstein M
    Int J Geriatr Psychiatry; 2007 Jun; 22(6):536-42. PubMed ID: 17096467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that Abeta42 plasma levels in presenilin-1 mutation carriers do not allow for prediction of their clinical phenotype.
    De Jonghe C; Cras P; Vanderstichele H; Cruts M; Vanderhoeven I; Smouts I; Vanmechelen E; Martin JJ; Hendriks L; Van Broeckhoven C
    Neurobiol Dis; 1999 Aug; 6(4):280-7. PubMed ID: 10448055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of beta-amyloid (1-42) in Alzheimer's disease and mild cognitive impairment.
    Pesaresi M; Lovati C; Bertora P; Mailland E; Galimberti D; Scarpini E; Quadri P; Forloni G; Mariani C
    Neurobiol Aging; 2006 Jun; 27(6):904-5. PubMed ID: 16638622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees.
    Ertekin-Taner N; Graff-Radford N; Younkin LH; Eckman C; Adamson J; Schaid DJ; Blangero J; Hutton M; Younkin SG
    Genet Epidemiol; 2001 Jul; 21(1):19-30. PubMed ID: 11443731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Abeta levels do not reflect brain Abeta levels.
    Freeman SH; Raju S; Hyman BT; Frosch MP; Irizarry MC
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):264-71. PubMed ID: 17413317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased amyloid beta protein levels in children and adolescents with Down syndrome.
    Mehta PD; Capone G; Jewell A; Freedland RL
    J Neurol Sci; 2007 Mar; 254(1-2):22-7. PubMed ID: 17275850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
    Herukka SK; Helisalmi S; Hallikainen M; Tervo S; Soininen H; Pirttilä T
    Neurobiol Aging; 2007 Apr; 28(4):507-14. PubMed ID: 16546302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-beta protein transport across the blood-brain barrier in Alzheimer's disease.
    Matsumoto Y; Yanase D; Noguchi-Shinohara M; Ono K; Yoshita M; Yamada M
    Dement Geriatr Cogn Disord; 2007; 23(4):241-5. PubMed ID: 17310121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease.
    Blasko I; Kemmler G; Jungwirth S; Wichart I; Krampla W; Weissgram S; Jellinger K; Tragl KH; Fischer P
    Am J Geriatr Psychiatry; 2010 Nov; 18(11):973-82. PubMed ID: 20808106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment.
    Bouwman FH; Schoonenboom SN; van der Flier WM; van Elk EJ; Kok A; Barkhof F; Blankenstein MA; Scheltens P
    Neurobiol Aging; 2007 Jul; 28(7):1070-4. PubMed ID: 16782233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anatomically-distinct genetic associations of APOE epsilon4 allele load with regional cortical atrophy in Alzheimer's disease.
    Filippini N; Rao A; Wetten S; Gibson RA; Borrie M; Guzman D; Kertesz A; Loy-English I; Williams J; Nichols T; Whitcher B; Matthews PM
    Neuroimage; 2009 Feb; 44(3):724-8. PubMed ID: 19013250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.